Sanofi: raises FY EPS target
(CercleFinance.com) - Sanofi has announced that it has raised its business EPS growth guidance for 2020, now expecting growth of between 6% and 7% at constant exchange rates (CER), barring major unforeseen adverse events.
Also at CER, the healthcare group reported Q2 business net income that is up 5.6% at 1,601 million euros, meaning EPS that is up 4.8% at 1.28 euro (1.18 euro excluding the revaluation of Regeneron shares it retained).
Sales reached 8,207 million euros, down 4.9% as reported and 3.4% at CER, with the strong performance of Dupixent more than offset by the negative effects of Covid-19 on vaccines, general medicine and consumer healthcare.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
Also at CER, the healthcare group reported Q2 business net income that is up 5.6% at 1,601 million euros, meaning EPS that is up 4.8% at 1.28 euro (1.18 euro excluding the revaluation of Regeneron shares it retained).
Sales reached 8,207 million euros, down 4.9% as reported and 3.4% at CER, with the strong performance of Dupixent more than offset by the negative effects of Covid-19 on vaccines, general medicine and consumer healthcare.
Copyright (c) 2020 CercleFinance.com. All rights reserved.